The neuromuscular transmission monitor market is valued at US$2,094 million in 2026 and is projected to reach US$2,664.15 million by 2033 at a 3.5% CAGR.
Growth is driven by mandatory quantitative neuromuscular blockade monitoring guidelines and increasing robotic-assisted surgical procedures.
Nerve Stimulating Devices/Monitors lead the market with a 67.0% share in 2026 because they are the core equipment required for neuromuscular monitoring.
North America dominates the market with a 41.0% share in 2026, supported by strong hospital infrastructure and long-term procurement agreements.
A major opportunity is the development of compact, cost-effective quantitative monitors for ambulatory surgical centers.